The European Medicines Agency has recommended restricting the use of the antibiotic telithromycin for bronchitis, sinusitis and tonsillitis/pharyngitis.
It says that it should only be used for bacterial resistant strains that are resistant to macrolide or beta-lactam antibiotics.
The agency said no such restrictions were recommended for the drug's remaining indication, the treatment of community-acquired pneumonia.
It has been carrying out a comprehensive review of the safety and effectiveness of telithromycin since January 2006.
Finalising the review at its March 2007, it concluded that its use was associated with a worsening of myasthenia gravis (which can be life-threatening), transient loss of consciousness, and temporary visual disturbances.
Severe problems with the liver have been reported rarely, but do not occur more frequently than with other relevant antibiotic medicines.